A Case of Dermatomyositis and Anti-EJ Autoantibody with Chronic Intestinal Pseudoobstruction Successfully Treated with Octreotide
Table 1
Characteristics of CIPO complicated with connective tissue disease treated with octreotide.
Diagnosis
Sex/age
Octreotide (dosage, routes of administration)
Effect
Scleroderma
Raynaud’s phenomenon
Diminished esophageal peristalsis
ILD
Diarrhea
Constipation
Antibodies and other features
Soudah et al. 1991
SSc
M/63
50 μg, SC
+
+
+
n.a.
+
+
+
Myopathy
SSc
F/65
50 μg, SC
+
+
−
n.a.
+
+
−
SSc
F/60
50 μg, SC
+
+
+
n.a.
−
+
+
SSc
M/57
50 μg, SC
+
+
−
n.a.
−
+
+
SSc
M/55
50 μg, SC
+
+
+
n.a.
−
+
+
Kobayashi et al. 1993
SSc
F/26
50 μg, SC
+
+
+
n.a.
n.a.
+
−
Lanting et al. 1993
SSc/PM
F/51
50 μg, SC
+
+
n.a.
+
+
+
−
Yamamoto et al. 1994
SSc
F/29
100 μg, SC
+
+
n.a.
n.a.
+
+
+
α-RNP, myopathy
Ono et al. 1996
SSc
F/28
100 μg, SC
+
+
+
n.a.
+
−
+
SSc
F/47
100 μg, SC
+
+
+
n.a.
+
−
−
Kanbe et al. 1996
SSc
F/61
100 μg, SC
+
+
+
n.a.
+
−
+
Ishikawa et al. 1999
SSc
F/66
SC
+
+
+
+
+
+
+
SSc/PM
F/35
SC
+
+
+
+
−
−
+
α-RNP, Ku
Perlemuter et al. 1999
SS
F/19
100 μg, SC
+
−
−
n.a.
n.a.
−
+
α-RNP, SSA
SLE
F/52
100–400 μg, SC
+
−
−
n.a.
n.a.
+
+
α-RNP, DNA
SSc
F/70
50–100 μg, SC
+
+
+
+
n.a.
−
+
α-Scl-70, Jo-1, PM-1
Descamps et al. 1999
SSc/PM
F/53
75 μg, SC
+
+
+
n.a.
n.a.
−
+
Dysphagia
Matsuki et al. 2000
SSc
M/64
50 μg, SC
+
+
+
n.a.
+
−
+
SSc
F/65
100 μg, SC
−
+
+
+
+
−
+
α-Scl-70
Marie et al. 2001
PM
M/55
50 μg, SC
+
−
−
−
−
−
+
Malcolm and Ellard 2001
SSc
F/75
50 μg, SC
−
+
+
−
+
+
−
Intestinal perforation
Suzuki et al. 2005
SSc/PM
F/31
100 μg, SC
−
+
+
+
−
−
+
α-Ku
Leonardi et al. 2010
SLE
F/51
50 μg, SC
−
−
n.a.
+
n.a.
−
+
PSL pulse was effective
Our case 2016
DM
F/38
100 μg IV, 50 μg SC, 30 mg IM
+
−
−
+
+
+
+
α-RNP, SSA, EJ
Dosage was not available, partial response. ILD: interstitial lung disease; SSc: systemic sclerosis; SS: Sjögren’s syndrome; PM: polymyositis; DM: dermatomyositis; SLE: systemic lupus erythematosus; n.a.: not available.
We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.
